Among patients with asthma who received four doses of depemokimab over 2 years, the annualized exacerbation rate was low, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results